Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors (Q34257256)

31 July 2017

title

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors (English)

1 reference

31 July 2017

author name string

Christina M Annunziata

1

1 reference

31 July 2017

Elise C Kohn

2

1 reference

31 July 2017

Patricia LoRusso

3

1 reference

31 July 2017

Nicole D Houston

4

1 reference

31 July 2017

Robert L Coleman

5

1 reference

31 July 2017

Manuela Buzoianu

6

1 reference

31 July 2017

Gabriel Robbie

7

1 reference

31 July 2017

Robert Lechleider

8

1 reference

31 July 2017

publication date

28 February 2012

1 reference

Investigational New Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

31

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

77-84

1 reference

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Peripheral neuropathy induced by microtubule-stabilizing agents.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 as a target for ovarian cancer therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 as a novel molecular marker and target in glioblastoma multiforme

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 expression is associated with aggressive features in ovarian carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Differential regulation of EphA2 in normal and malignant cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9801-2

Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9801-2

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-012-9801-2

Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553417

10.1007/S10637-012-9801-2

28 October 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference